Reach Us +44-1625-708989
Hemoglobin Outcomes during Administration of Continuous Erythropoietin Receptor Activator (C.E.R.A): A Prospective, Observational, Multicenter Study | OMICS International
ISSN: 2161-0959
Journal of Nephrology & Therapeutics

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Hemoglobin Outcomes during Administration of Continuous Erythropoietin Receptor Activator (C.E.R.A): A Prospective, Observational, Multicenter Study

Dirk Henrich1* and Michael Rambausek2

1Dialysis Center Saarlouis, Saarlouis, Germany

2Dialysis Center Mörikestrasse, Heilbronn, Germany

*Corresponding Author:
Dirk Henrich
Dialysis Center Saarlouis
Vaubanstr 27, 66740 Saarlouis
Saarland, Germany
Tel: +49 6831 986 1777
E-mail: [email protected]

Received Date: August 19, 2015; Accepted Date: August 27, 2015; Published Date: September 04, 2015

Citation: Henrich D, Rambausek M (2015) Hemoglobin Outcomes during Administration of Continuous Erythropoietin Receptor Activator (C.E.R.A): A Prospective, Observational, Multicenter Study. J Nephrol Ther 5:211. doi:10.4172/2161-0959.1000211

Copyright: © 2015 Henrich D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Nephrology & Therapeutics


Objective: To evaluate Hb outcomes in patients with dialysis-dependent or non-dialysis dependent chronic kidney disease (CKD) receiving continuous erythropoietin receptor activator (C.E.R.A.) therapy under routine conditions at specialist nephrology centers in Germany.

Methods: In a 12-month, prospective, observational, multicenter study, Hb outcomes were assessed in 1,580 patients with CKD (1,184 dialysis-dependent, 326 non-dialysis dependent) given once-monthly C.E.R.A. under routine conditions.

Results: Across the total study population, mean hemoglobin was in the range 11.4–11.6 g/dL at all post-baseline visits. In the 962 patients on hemodialysis who were pretreated with ESA including C.E.R.A., mean (SD) hemoglobin was 11.4 (1.2) g/dL at baseline and 11.5 (1.1) g/dL at month 12; the mean (SD) number of C.E.R.A. dose changes was 3.0 (2.4). For the 227 non-dialysis dependent patients without prior ESA therapy, mean hemoglobin values were 10.6 (1.1) g/dL at baseline and 11.6 (1.3) g/dL at month 12, with a mean of 1.0 (1.4) dose changes. Presence of diabetic nephropathy showed no clinically relevant effect on hemoglobin response in either group. Overall, the proportion of patients with every hemoglobin measurement within narrow (≤ 2 g/dL) pre-specified ranges was low (<10%), but higher for the range 10.0–13.0 g/dL (28.7%), reflecting the known fluctuation in hemoglobin values over time. Patients managed at large centers were more likely to have hemoglobin range in the range 10–13 g/dL throughout the 12-month study, suggesting closer anemia management. In total, five patients (0.3%) discontinued C.E.R.A. due to adverse events.

Conclusion: Switching dialysis-dependent patients from more frequent ESA regimens to once-monthly C.E.R.A. therapy or initiating once-monthly C.E.R.A. de novo in predialysis CKD patients appears to be an effective therapeutic strategy regardless of diabetic status.


C.E.R.A.; Dosing; Efficacy; ESA; Hemodialysis; Observational’


Anemia is a frequent complication of chronic kidney disease (CKD), affecting over a quarter of those with mild disease (stages 1-2), over half with CKD stage 4 and three-quarters of patients on dialysis [1]. The primary etiology of anemia in CKD is erythropoietin deficiency (‘renal anemia’), which intensifies as kidney dysfunction progresses [2], and is often compounded by functional iron deficiency [3]. In addition to the well-recognized and debilitating symptoms of anemia such as fatigue, anemia is associated with reduced quality of life [4], increased risk of progression to end-stage renal disease, cardiovascular events and death [5,6], particularly as the severity of anemia worsens [6]. Recognizing this, the Kidney Disease Improving Global Outcomes (KDIGO) initiative advises that hemogloblin (Hb) level be monitored regularly in all patients with CKD [7]. Erythropoiesis-stimulating agent (ESA) therapy remains the mainstay of anemia therapy in patients with CKD. It is recommended that administration of ESAs should be based on individualized management, taking into account the clinical situation and specific risks in particular patients, and that in general ESAs not be used to maintain Hb level above 11.5 g/dL, with an upper threshold of 13 g/dL in all cases [7].

Maintenance of Hb level will often require long-term administration of ESA therapy. Typically, epoetin alfa or epoetin beta are given twice or three times a week, and darbepoetin every 2–4 weeks during the maintenance phase. Longer dosing intervals would be time-saving for staff and convenient for patients, particularly not on dialysis, but the half-lives of these therapies are relatively short (up to 9 hours for epoetin alfa and beta [8] and approximately 25 hours for darbepoetin alfa [9]). Continuous erythropoietin receptor activator (C.E.R.A.) is a modified recombinant human erythropoietin which has a longer half-life (approximately 132 hours), a relatively low binding affinity for the erythropoiesis receptor and low systemic clearance in CKD patients [10]. Consequently, C.E.R.A. can be dosed every two weeks in dialysis-dependent patients and once a month in non-dialysis dependent CKD patients during the correction phase and monthly (intravenously or subcutaneously) in all patients during maintenance therapy [11]. Randomized trials have demonstrated the effectiveness of C.E.R.A. using different dosing regimens in dialysis dependent patients converted from other ESA therapies [12-16], and in ESAnaïve non-dialysis dependent patients [17-19]. In the absence of protocol-stipulated Hb monitoring and ESA dosing, however, anemia management and C.E.R.A. administration will vary between centers and results from controlled trials may not be replicated in routine practice.

In particular, the use of C.E.R.A. in specific patient subpopulations, for example those with diabetes, and at specific types of centers, remains largely unexamined outside the confines of randomized studies.

Against this background, a prospective, observational study was undertaken to evaluate Hb outcomes in patients with dialysisdependent or non-dialysis dependent CKD receiving C.E.R.A. therapy under routine conditions at specialist nephrology centers in Germany.


Study design and conduct

This was a 12-month, prospective, observational study of adult patients with dialysis dependent or non-dialysis dependent CKD in whom the treating physician had decided to initiate C.E.R.A. therapy. C.E.R.A. dosing was at the discretion of the treating physician. The study was conducted at nephrology centers in Germany during December 2009 to February 2013. Written informed consent was obtained from all patients


It was planned to recruit between 1,500 and 2,250 patients aged >18 years in whom C.E.R.A. therapy had been initiated by their physician. Eligible patients were required to be free of malignancy and serious hematological or infectious disease, have a life expectancy of at least 12 months, be free of acute bleeding for the 16 weeks prior to enrollment, and not be taking part in an interventional trial. Female patients were not enrolled if they were pregnant or breast feeding. All patients recruited at a center were to be either receiving hemodialysis or nondialysis dependent, to improve the homogeneity of data collection from each center.

Data collection

Data obtained at routine clinic visits were captured. Demographic information and clinical characteristics at baseline were recorded, with information on ESA medication in the 16 weeks prior to study entry and reason for initiation of C.E.R.A. therapy. At subsequent clinical visits, information was documented regarding C.E.R.A. dose, Hb level, other laboratory values including serum ferritin, transferrin saturation (TSAT) and C-reactive protein (CRP). Hb levels were obtained retrospectively for the 16 weeks prior to study entry, and prospectively during the 12-month evaluation period.

At the final visit of the 12-month study, the treating physician recorded whether the patient had discontinued the study, discontinued C.E.R.A. therapy, the reason for C.E.R.A. discontinuation if applicable, switch to another ESA therapy, and physician-reported and patientreported satisfaction with C.E.R.A. therapy (‘very satisfied’, ‘satisfied’, ‘undecided’ or ‘not satisfied’).

Data analysis

Patients were analyzed according to (i) whether they were receiving dialysis at study entry (CKD stage 5) or were non-dialysis dependent (CKD ≤ 4) (ii) receipt of ESA therapy (including C.E.R.A. therapy) in the 16 weeks prior to study entry (iii) whether the cause of CKD was diabetic nephropathy or not (iv) whether they received one or more C.E.R.A. dose modification or not and (v) according to the size of center. Study centers were categorized as large (treating >100 patients at the time of study initiation) or small (≤ 100 patients).

Pre-defined efficacy variables included the proportions of patients with Hb response during months 0–12 and months 6–12; the maximum intra-individual fluctuation in Hb values from the individual mean during months 0–12; changes in laboratory parameters over months 0–12; the proportion of patients discontinuing the study or C.E.R.A. therapy; and physician and patient satisfaction with C.E.R.A. therapy. Hb response was defined as Hb within the following ranges at every study visit: 10.0–12.0 g/dL, 11.0–12.0 g/dL and 11.0–13.0 g/dL. Post hoc, a further Hb range (10–13 g/dL) was defined.

Although no formal sample size calculation was performed, it was planned to recruit a minimum of 50 patients per center, to achieve a representative sample of the local population of patients with CKD. Furthermore, it was planned that at least 30 centers should take part in the study to provide an adequate number of large and small centers for meaningful comparison, and to achieve a large population for analysis (~1500 patients).

Data were summarized and presented descriptively. Efficacy data were analyzed for patients of the intent-to-treat (ITT) population, defined as all patients who received at least one dose of C.E.R.A. with at least one post-baseline efficacy assessment. Safety analyses were based on all patients who received at least one dose of C.E.R.A. and provided at least one safety assessment.


Study population

In total, 1,580 patients were recruited at 33 centers. Of these, 33 patients were excluded from analyses since no baseline or subsequent information was provided (n=17) or because C.E.R.A. administration was not documented (n=16). The safety population thus comprised 1,547 patients. A further 37 patients were excluded from the ITT population, most frequently due to no study visit (Figure 1), such that the ITT population included 1,510 patients. The study was discontinued prematurely by 469/1,510 patients (31.1%), with death due to underlying disease (n=130) and discontinuation of treatment (n=114) the most common reasons (Figure 1).


Figure 1: Patient disposition.

In the ITT population, 1,184 patients (78.4%) were receiving dialysis, of which the majority (962; 81.3%) had received ESA therapy in the 16 weeks prior to study entry (Table 1). The remaining 326 patients (21.6%) were non-dialysis dependent; 227 of these patients (69.6%) had not received any ESA therapy in the preceding 16 weeks. The most frequent underlying cause of CKD was diabetic nephropathy in both the dialysis-dependent and non-dialysis dependent cohorts (Table 1). Concomitant conditions included heart failure (12.7%), coronary artery disease (30.3%), secondary hyperparathyroidism (30.6%), type 1 diabetes (2.2%), type 2 diabetes (39.9%), dyslipidemia (14.8%) and hypertension (82.1%). The majority of patients (56.2%) were managed at centers with 100 patients or fewer (Table 1).

  Dialysis (N=1,184) Non-dialysis (N=326) Total (n=1,510)
Age, years 68.0 (13.8) 71.8 (13.3) 68.8 (13.8)
Age <65 years, n (%) 402 (34.0) 70 (21.5) 472 (31.3)
Male gender, n (%) 705 (59.5) 168 (51.5) 873 (57.8)
Weight (kg) 77.1 (16.5) 79.7 (17.0) 77.7 (16.6)
Body mass index (kg/m2) 27.0 (5.3) 28.0 (5.6) 27.2 (5.4)
Underlying disease, n (%)
   Diabetic nephropathy 377 (31.8) 101 (31.0) 478 (31.7)
   Hypertensive nephrosclerosis 244 (20.6) 128 (39.3) 372 (24.6)
   Glomerulonephritis 178 (15.0) 21 (6.4) 199 (13.2)
   Pyelonephritis/interstitial nephritis 68 (5.7) 24 (7.4) 92 (6.1)
   Polycystic kidney disease 71 (6.0) 16 (4.9) 87 (5.8)
   Other 326 (27.5) 73 (22.4) 399 (26.4)
   Missing 2 (0.2) 0 2 (0.1)
ESA therapy in 16 weeks prior to study entry, n (%)a
   Any 962 (81.3) 99 (30.4) 1,061 (70.3)
   C.E.R.A. 435 (36.7) 47 (14.4) 482 (31.9)
Darbepoetin alpha 212 (17.9) 45 (13.8) 257 (17.0)
Epoetin beta 229 (19.3) 6 (1.8) 235 (15.6)
Epoetin alpha 131 (11.1) 0 (-) 131 (8.7)
Biosimilar 107 (9.0) 1 (0.3) 108 (7.2)
Frequency of ESA therapy in 16 weeks prior to study entry, n (%)a
   More than once a week 443 (37.4) 0 (-) 443 (29.3)
   Once a week 343 (29.0) 14 (4.3) 357 (23.6)
   Once every two weeks 62 (5.2) 38 (11.7) 100 (6.6)
   Once every three weeks 11 (0.9) 4 (1.2) 15 (1.0)
   Once every four weeks 588 (49.7) 49 (15.0) 637 (42.2)
   Other 21 (1.8) 3 (0.9) 24 (1.6)
   Missing 1 (0.1) 0 (-) 1 (0.1)
Reason for C.E.R.A. initiation, n (%)b
   Once-monthly administration 1141 (96.4) 285 (87.4) 1,426 (94.4)
   Long shelf-life 578 (48.8) 75 (23.0) 653 (43.2)
   Good control of Hb levels 186 (15.7) 121 (37.1) 307 (20.3)
   Other 21 (1.8) 0 (-) 21 (1.4)
   Missing 1 (0.1) 0 (-) 1 (0.1)
   Large center, n (%),c 563 (47.6) 99 (30.4) 662 (43.8)
   Small center, n (%),c 621(52.4) 227 (69.6) 848 (56.2)

Table 1: Baseline characteristics and previous ESA therapy.

Data on iron therapy were collected as part of standard capture of information about concomitant medication during the study. Administration of oral iron therapy was documented in 447 patients (29.6%) and intravenous iron therapy in 697 patients (46.2%), with a higher reported rate of iron therapy (of any type) in dialysis-dependent patients (84.2%) than non-dialysis dependent patients (45.1%). Intravenous preparations predominated in the dialysis dependent subgroup (695/1,184 [58.7%] compared to 302/1,184 [25.5%] for oral iron) and oral iron predominated in the non-dialysis dependent patients (145/326 [44.5%] compared to 2/326 [0.6%] for intravenous iron).

C.E.R.A. therapy

Among the patients who had receiving ESA therapy in the 16 weeks prior to study entry, the most frequent agent was C.E.R.A. (36.7% of dialysis-dependent and 14.4% of non-dialysis dependent patients) (Table 2). Physicians reported the most frequent reason for initiation of C.E.R.A to be once-monthly administration (94.4%) (Table 2). During the study, the median number of C.E.R.A. doses per month was 1.0 (interquartile range 1.0, 1.0) at each study visit to month 12. The mean (SD) dose increased slightly from baseline (109 [76] μg) to the month 12 visit (121 [99] μg), with a mean of 2.9 dose changes in the dialysis-dependent cohort compared to 1.0 dose changes in the non-dialysis dependent group (Table 2). In total, 490 patients (32.5%) discontinued C.E.R.A. therapy (Figure 1). Among those who discontinued, 169 (34.5%) switched to a different ESA therapy (11.2% of the ITT population).

  Dialysis (N=1,184) Non-dialysis (N=326) Total (n=1,510)
  All patients (n=1,184) ESA prior to study entry (n=962) All patients (n=326) No ESA prior to study entry (n=227)
Route of administration, n (%)
Intravenous 1085 (91.6) 909 (94.5) 0 (0) 0 (0) 1085 (71.9)
 Subcutaneous 76 (6.4) 36 (3.7) 317 (97.2) 220 (96.9) 393 (26.0)
Both 23 (1.9) 17 (1.8) 9 (2.8) 7 (3.1) 32 (2.1)
C.E.R.A. dose at baseline, μg
Mean (SD) 118 (81) 121 (82) 77 (39) 76 (37) 109 (76)
   Median (range) 100 (30, 360) 100 (30, 360) 75 (30, 200) 75 (30, 200) 100 (30, 360)
C.E.R.A. dose at month 12, μg
Mean (SD) 131 (104) 132 (106) 79 (60) 79 (58) 121 (99)
Median (range) 100 (30, 1080) 100 (30, 1080) 68 (30, 400) 75 (30, 400) 100 (30, 1080)
≥1 C.E.R.A. dose change, n (%) 942 (79.6) 780 (81.1) 169 (51.8) 118 (52.0) 1111 (73.6)
No C.E.R.A. dose change, n (%) 242 (20.4) 182 (18.9) 157 (48.1) 109 (48.0) 399 (26.4)
C.E.R.A. dose changes, n (%)
 Mean (SD) 2.9 (2.4) 3.0 (2.4) 1.0 (1.3) 1.0 (1.4) 2.5 (2.4)
 Median (range) 3 (0, 14) 3.0 (0, 14) 1 (0, 6) 1.0 (0, 6) 2 (0, 14)

Table 2: C.E.R.A. therapy.


Across the total study population, mean Hb was in the range 11.4– 11.6 g/dL at all post-baseline visits (Figure 2). In the dialysis-dependent patients, mean (SD) Hb level was 11.3 (1.3) g/dL at study entry, and 11.6 (1.1) g/dL at month 12; values in the subpopulation treated with ESA therapy before study entry were 11.4 (1.2) g/dL and 11.5 (1.1) g/dL. Mean (SD) Hb level was lower in the non-dialysis dependent subgroup at baseline (10.9 [1.3] g/dL) but identical to the dialysis-dependent cohort by month 12 (11.6 g/dL in both groups), an effect attributable to increase in Hb level after initiation of C.E.R.A. in the 227 ESA-naïve non-dialysis dependent patients (Table 3). This improvement accounted for the slight increase in mean Hb level in the total study population.

  Dialysis Non-dialysis Total
  All patients (n=1,184) ESA prior to study entry (n=962) All patients (n=326) No ESA prior to study entry (n=227)  
Hb, g/dL, mean (SD)
Baseline 11.3 (1.3) 11.4 (1.2) 10.9 (1.3) 10.6 (1.1) 11.2 (1.3)
Month 12  11.6 (1.1) 11.5 (1.1) 11.6 (1.2) 11.6 (1.3) 11.6 (1.1)
Maximum Hb fluctuation, mean (SD)a 1.6 (0.8) 1.6 (0.8) 1.3 (0.8) 1.4 (0.8) 1.5 (0.8)
Hb response during months 0–12, n (%)b
10.0–12.0 g/dL 67 (5.7) 50 (5.2) 29 (8.9) 18 (7.9) 96 (6.4)
11.0–12.0 g/dL 3 (0.3) 2 (0.2) 2 (0.6) 1 (0.4) 5 (0.3)
11.0–13.0 g/dL 76 (6.4) 61 (6.3) 33 (10.1) 18 (7.9) 109 (7.2)
10.0–13.0 g/dL 322 (27.2) 266 (27.7) 112 (34.4) 70 (30.8) 434 (28.7)
Hb response during months 6–12, n (%)b
10.0–12.0 g/dL 169 (14.3) 135 (14.0) 33 (10.1) 19 (8.4) 202 (13.4)
11.0–12.0 g/dL 28 (2.4) 19 (2.0) 7 (2.1) 3 (1.3) 35 (2.3)
11.0–13.0 g/dL 173 (14.6) 138 (14.3) 29 (8.9) 18 (7.9) 202 (13.4)
10.0–13.0 g/dL 471 (39.8) 386 (40.1) 69 (21.2) 45 (19.8) 540 (35.8)

Table 3: Hb outcomes according to requirement for dialysis.


Figure 2: Hb level in the 16 weeks prior to study entry and during months 0–12 (a) all patients (b) dialysis-dependent patients who received ESA therapy in the 16 weeks prior to study entry (c) non-dialysis dependent patients who did not receive ESA therapy prior to study entry. Values are shown as mean (SD).

There was a significant inverse correlation between C.E.R.A. dose and Hb level in the study population overall (r=-0.319 [Pearson coefficient]; p<0.001). The correlation was r=-0.366 (p<0.001) for the subpopulation of dialysis-dependent patients previously treated with ESA therapy, and r=-0.305 (p<0.001) for the cohort of ESA-naïve nondialysis dependent patients.

Hb fluctuation and response rates

Mean (SD) intra-individual Hb fluctuation from the individual mean during the 12-month study was 1.5 (0.8) g/dL overall, with greater fluctuation in patients receiving dialysis (Table 3). The maximum intra-individual Hb fluctuation was ≤ 1 g/dL in 393 patients (26.0%) (259/1,184 dialysis-dependent patients [21.9%]; 134/326 non-dialysis dependent patients [41.1%]).

The proportion of patients with every Hb measurement within the pre-specified windows of 10.0–12.0 g/dL, 11.0–12.0 g/dL and 11.0–13.0 g/dL during months 0–12 was low, although somewhat higher during only months 6–12 (Table 3), as would be expected following time for dose adjustments. Based on the wider Hb window of 10–13 g/dL, analyzed post hoc, 28.7% of patients remained within this window at all of the 12 study visits. Corresponding to the greater Hb fluctuation in dialysis patients, the proportion of patients within the predefined Hb windows was slightly higher in the non-dialysis dependent subpopulation (Table 3). Diabetic nephropathy did not adversely affect Hb levels or Hb response to C.E.R.A. in either the dialysis-dependent or non-dialysis dependent groups (Supplementary Table 1). Patients who required no C.E.R.A. dose modification exhibited slightly higher Hb response rates than those with one or more dose change during months 0–12, as might be anticipated. Of interest, a higher proportion of patients managed at large centers remained within 10-13 g/dL at all 12 study visits than those at small centers, particularly for non-dialysis dependent patients (Table 4). This may be related to the finding that C.E.R.A. dose was managed more closely at large centers: the mean (SD) number of dose changes was 3.0 (2.6) (median 3, range 0–14) versus 2.0 (2.1) (median 1, range 0–12) at small centers.

  Dialysis Non-dialysis
≥ 1 C.E.R.A dose change n=942 n=169
Hb, g/dL, mean (SD)    
Baseline 11.3 (1.3) 10.8 (1.2)
Month 12 11.5 (1.1) 11.4 (1.2)
Maximum Hb fluctuation, mean (SD)a 1.7 (0.8) 1.4 (0.8)
Hb response during months 6–12, n (%)b
10.0–12.0 g/dL 46 (4.9) 11 (6.5)
11.0–12.0 g/dL 1 (0.1) 1 (0.6)
11.0–13.0 g/dL 49 (5.2) 15 (8.9)
10–13.0 g/dL 241 (25.6) 49 (29.0)
No C.E.R.A. dose change n=242 n=157
Hb, g/dL, mean (SD)
Baseline 11.4 (1.3) 11.1 (1.3)
Month 12 12.0 (1.1) 12.1 (1.2)
Maximum Hb fluctuation, mean (SD)a 1.2 (0.7) 1.2 (0.8)
Hb response during months 6–12, n (%)b
10.0–12.0 g/dL 21 (8.7) 18 (11.5)
11.0–12.0 g/dL 2 (0.8) 1 (0.6)
11.0–13.0 g/dL 27 (11.2) 18 (11.5)
10–13.0 g/dL 81 (33.5) 63 (40.1)
Patients at large centers n=563 n=99
Hb, g/dL, mean (SD)
Baseline 11.2 (1.3) 10.8 (1.3)
Month 12 11.5 (1.1) 11.3 (1.2)
Maximum Hb fluctuation, mean (SD)a 1.6 (0.7) 1.2 (0.7)
Hb response during months 6–12, n (%)b    
10.0–12.0 g/dL 34 (6.0) 17 (17.2)
11.0–12.0 g/dL 2 (0.4) 2 (2.0)
11.0–13.0 g/dL 42 (7.5) 13 (13.1)
10–13.0 g/dL 170 (30.2) 48 (48.5)
Patients at small centers n=621 n=227
Hb, g/dL, mean (SD)    
Baseline 11.4 (1.3) 11.0 (1.3)
Month 12 11.6 (1.2) 11.8 (1.3)
Maximum Hb fluctuation, mean (SD)a 1.6 (0.8) 1.4 (0.8)
Hb response during months 6–12, n (%)b
10.0–12.0 g/dL 33 (5.3) 12 (5.3)
11.0–12.0 g/dL 1 (0.2) 0 (0)
11.0–13.0 g/dL 34 (5.5) 20 (8.8)
10–13.0 g/dL 152 (24.5) 64 (28.2)

Table 4: Hb response according to C.E.R.A. dose modifications and study centre size.

Laboratory values

There was no consistent change in mean (SD) serum ferritin levels during the study from the month 1 visit onwards. The lowest value was observed at baseline (mean [SD] 403 [365] ng/mL), after which mean values remained in the range 413 to 567 ng/mL. At month 12, mean (SD) serum ferritin was 479 (354) ng/mL. Similarly, the lowest TSAT level was at baseline (mean [SD] 24.4% [11.8%]), thereafter showing minor fluctuations within the range 25.7% to 28.2% with a mean (SD) level of 27.0% (11.8%) at month 12. The lower end of the interquartile range for TSAT varied between 17.0% and 19.0% during the study. Mean CRP level showed no pattern of change during the study: mean (SD) values were 12.7 (27.1) nmol/L at baseline and 10.7 (22.2) nmol/L at month 12, (median 4.7 nmol/L at both time points) with minor fluctuations at other time points.

Physician and patient assessment

At the final study visit, 45.4%, 39.9%, 9.0% and 2.1% of physicians were very satisfied, satisfied, undecided or dissatisfied with C.E.R.A. therapy. For patients, the corresponding proportions were 39.3%, 47.2%, 7.5% and 1.1%. Data were missing in the remaining cases.


During the 12-month course of this observational trial, oncemonthly treatment with C.E.R.A. maintained mean Hb level within the range 11.4–11.6 g/dL in a large cohort of patients with dialysis dependent or non-dialysis dependent CKD. Hb level remained unchanged under once-month C.E.R.A. in dialysis-dependent patients who had been receiving ESA therapy before study entry, approximately half of whom had previously been dosed at least every two weeks with non-C.E.R.A. preparations. In the 70% of non-dialysis dependent patients who were ESA-naïve at baseline, mean Hb showed an initial rise after C.E.R.A. initiation then remained stable to month 12. The presence of diabetic nephropathy did not adversely affect the Hb response to C.E.R.A. Although patients who did not require any C.E.R.A. dose change were more likely to remain within target Hb range at all 12 study visits, patients managed at large centers – where dose changes were more frequent – were more likely to remain within target Hb ranges, suggesting closer anemia management.

The interval between C.E.R.A. doses was consistently one month throughout the 12-month study, with few exceptions. Dose changes were infrequent, with a mean of three dose changes over 12 months in the dialysis-dependent patients, in whom Hb fluctuation is known to be more marked, and a mean of only one dose change in the ESA-naïve non-dialysis patients following the start of C.E.R.A. therapy. Over the 12-month study, patients with a dose modification were less likely to remain within specific Hb windows but after the first six months they were marginally more likely to do so, presumably because of the early dose adjustments. This is consistent with a previous observational study of 918 patients receiving C.E.R.A., in which patients receiving at least one dose change were more likely to remain within pre-specified ranges for Hb than those with no dose change [20].

Patients with CKD exhibit wide fluctuations in Hb levels [21,22] and it is notoriously difficult to sustain Hb levels within a specific target range consistently over an extended period during ESA therapy [23]. Naturally occurring Hb fluctuations caused by various factors such as concomitant illnesses, inflammation or iron therapy [21,24,25] are exacerbated by intermittent bursts of erythropoietic activity stimulated by ESA administration. A one-year study of 68 ESA-treated patients receiving dialysis in the Netherlands revealed that no patient remained within the Hb target range of 11–12 g/dL and that mean intra-individual Hb fluctuation was >1.0 g/dL [22], similar to our observations in the dialysis-dependent cohort. Their analysis also showed that fluctuation is greater during ESA therapy [22], as might be expected given the intermittent nature of ESA administration. Another observational study of 1,428 patients on hemodialysis found that only 4% of patients could be maintained within a 2 g/dL Hb window over 12 months [26], while a mean fluctuation ≥ 1.0 g/dL was observed elsewhere in a series of 98 patients on hemodialysis patients receiving epoetin or darbepoetin over a nine-month period [27]. Typically, hemodialysis patients exhibit a mean of 3.1 Hb fluctuations each year, with a mean size of 2.5 g/dL [28]. Non-dialysis CKD patients receiving ESA also show Hb variations but to a lesser extent than dialysis-treated individuals [22], consistent with our findings [22]. Against this background, considerable variation in Hb levels would be expected in the current study over a one-year period, especially since almost 80% of patients were on hemodialysis. Other studies of C.E.R.A. under routine conditions in various CKD settings have employed a three-month evaluation period [20,29-31]. Accordingly, the proportion of patients with every Hb level within prespecified windows was lower than reported elsewhere. For example, in other observational studies Hb was maintained within the narrow window of 11–12 g/dL in 15-20% of patients with hemodialysis dependent CKD [26], non-dialysis dependent CKD [29] or following kidney transplantation [31] over three-month evaluation periods, versus almost no patients here over a 12-month period. For the wider window of 10–13 g/dL, 65-75% of patients could be maintained in this range over a three-month period [26,32] but only 28.7% in the current 12-month trial (35.8% over months 6–12). Correspondingly, the mean intra-patient Hb variability in our population was 1.5 g/dL compared to only 0.5 g/dL over a period of three months in other publications [20,31]. In an observational study of 918 patients on hemodialysis, intra-patient Hb fluctuation increased to 1.4 g/dL when monitored over nine months [20], close to that observed in our population. Drawing comparisons of Hb fluctuation, or the proportion of patients maintained within specific Hb windows, under the routine conditions of this study versus data from controlled trials of C.E.R.A. therapy is generally unhelpful since the exclusion criteria in interventional trials have typically excluded patients with Hb fluctuation > 1 g/dL during a four-week screening period [12-15].

Dialysis patients were more likely to be receiving ESA at study entry than non-dialysis patients (81.3% versus 30.4%), and almost twice as likely to be receiving iron therapy, as would be anticipated given the greater loss of erythropoietin production and increasing frequency of anemia with worsening CKD [1]. Mean Hb was slightly higher than in non-dialysis dependent patients as a result. Nevertheless, 16.1% of hemodialysis patients had a Hb level ≤ 10 g/dL at study entry. Of note, although mean TSAT was approximately 26–28% during the study, the lower limit of the interquartile threshold was 17–19%, indicating the presence of functional iron deficiency in a sizeable number of patients.

Results from this study suggest that greater experience of managing C.E.R.A.-treated patients, as at the larger centers (≥ 100 patients), may be associated with slightly closer control of Hb levels. While mean Hb levels were generally comparable between large and small centers at baseline and at the end of the study, slightly higher Hb response rates were observed at larger centers despite the fact that larger centers had a higher proportion of patients on hemodialysis, in whom close Hb control is challenging. This appears to contradict the fact that C.E.R.A. dose was adjusted more often in patients managed at larger centers than at smaller centers and that, overall patients with dose changes were less likely to remain within Hb target windows. It is possible that C.E.R.A. dose changes were made more appropriately at the larger centers, possibly reacting sooner and in a more controlled manner than at less experienced smaller centers, but this remains speculative.

We recognize that the single-cohort design of this study prohibits efficacy comparisons with other treatment strategies, but a series of randomized trials has already shown that once-monthly dosing with C.E.R.A. achieves comparable Hb control to epoetin or darbepoetin [12-15]. The study was intended to evaluate once-monthly C.E.R.A. therapy based on local physician decision-making, in a typical population of dialysis-dependent or non-dialysis dependent CKD patients presenting to nephrology centers. As such, no control arm was included, few exclusion criteria were applied and both ESA-naïve and ESA-treated patients could be enrolled, to ensure wide applicability of findings. The large number of centers (n=33), including both large and small units, also contributed to the generalizability of the results. Methodological challenges to achieving accurate and comprehensive capture of data regarding adverse events in this observational study across a large number of centers meant that the study did not attempt to assess adverse events during C.E.R.A. therapy, since the robustness of any conclusions could not be assured. The safety of C.E.R.A. has been described elsewhere [12-19,32].

This non-interventional study assessed outcomes using once-monthly C.E.R.A. therapy over a one-year period based on substantial numbers of patients at both large and small centers, thus closely reflecting practice. As such, the findings are applicable to routine practice in patients with dialysis dependent or non-dialysis dependent CKD. In this largely unselected population, it is clear that Hb fluctuation is considerable over a one-year period, and the results highlight the challenge of maintaining patients within narrow Hb target ranges. Slightly tighter Hb control was observed in patients treated at large nephrology centers, suggesting that greater experience improves anemia management with C.E.R.A., although specific reasons for this were not discernible in the current dataset. Overall, switching patients from more frequent ESA regimens to once-monthly C.E.R.A. therapy or initiating once-monthly C.E.R.A. de novo in CKD patients with or without hemodialysis appears to be an effective therapeutic strategy regardless of diabetic status.


The study was supported by Roche Pharma AG, Germany. A first draft of the manuscript was developed by a freelance medical writer with funding from Roche, based on the clinical study report. The draft was revised by the authors, who gave final approval for submission.

Conflicts of interest

M Rambausek has received speaker’s honoraria and research funding from Roche. D Henrich has received a travel grant from Roche.


With grateful thanks to the study investigators and their teams. Matthias Anders, Leipzig; Jörg Baumann, Herford; Sabine Biernat, Varel; Alfred Bosch, Worms; Karl August Brensing, Bonn; Wilfried Dschietzig, Cottbus; Erika Eger, Berlin; Ervé Garnier, Remscheid; Klaus Gondolf, Schwetzingen; Syrus Hafezi, Mannheim; Steffen Hengst, Alsfeld Dirk Henrich, Saarlouis; Dorothee Hoffacker, Duisburg; Arnfried Klingbeil, Darmstadt; Manfred Küster, Varel; Frank Leistikow, Mannheim; Edgar Lensker, Nordhorn; Olaf Loke, Lüdenscheid; Manfred Lorenzen, Peine; Nexhat Miftari, Neckarsulm; Rainer Nowack, Lindau; Thomas Quaschning, Villingen-Schwenningen; Michael Rambausek, Heilbronn; Hauke Salto, Peine; Uwe Schirrmeister, Bad Harzburg; Alexander Schischma, Schwabach; Michael Scholl, Mühlhausen; Volker Schumann, Herne; Wolfgang Seeger, Berlin; Dietmar Sehland, Rostock; Efstratios Tatsis, Pinneberg; Edgar Frank Thiele, Georgsmarienhütte; Ulrich Tholl, Kleve; Theoharis Tsobanelis, Frankfurt; Peter Weidemann, Aachen; Stefan Zinn, Alsfeld.

The authors would like to thank Pr Nexhut Miftari for his substantial contributions to the study.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 12145
  • [From(publication date):
    October-2015 - Dec 19, 2018]
  • Breakdown by view type
  • HTML page views : 8358
  • PDF downloads : 3787

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri and Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry


[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version